TNGX (Tango Therapeutics) יחס שווי שוק לשווי בספרים

Tango Therapeutics is creating a comprehensive environment for combating tumors by combining genetic analysis with precise drug selection. The business is currently in an active funding stage, where development costs significantly exceed revenues, as captured by the 3.78 metric. Current price action confirms the company's status as an innovator implementing AI platforms and small molecules to radically overhaul immunotherapy.

This multiple compares the market value of the business with its net assets, determining the premium or discount to the book value of equity. This chart of market and book valuation metrics reflects investor expectations regarding the value of Tango Therapeutics (TNGX) intellectual property in the field of synthetic lethality and the potential of their pipeline of targeted drugs for treating resistant forms of cancer.